Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
DOI
 |
Free by publisher |
Open Access Green as soon as Postprint is submitted to ZB.
The chemokine receptor CCR7 is a promising target for rheumatoid arthritis therapy.
Cell. Mol. Immunol. 16, 791-799 (2018)
Publ. Version/Full Text
DOI
The chemokine receptor CCR7 and its ligands CCL19 and CCL21 guide the homing and positioning of dendritic and T cells in lymphoid organs, thereby contributing to several aspects of adaptive immunity and immune tolerance. In the present study, we investigated the role of CCR7 in the pathogenesis of collagen-induced arthritis (CIA). By using a novel anti-human CCR7 antibody and humanized CCR7 mice, we evaluated CCR7 as a target in this autoimmune model of rheumatoid arthritis (RA). Ccr7-deficient mice were completely resistant to CIA and presented severely impaired antibody responses to collagen II (CII). Selective CCR7 expression on dendritic cells restored arthritis severity and anti-CII antibody titers. Prophylactic and therapeutic treatment of humanized CCR7 mice with anti-human CCR7 mAb 8H3-16A12 led to complete resistance to CIA and halted CIA progression, respectively. Our data demonstrate that CCR7 signaling is essential for the induction of CIA and identify CCR7 as a potential therapeutic target in RA.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Collagen-induced Arthritis; Dendritic Cells; Monoclonal-antibody; Cutting Edge; Expression; Anti-cd3; Disease; Ccl21; Ccl19
ISSN (print) / ISBN
1672-7681
Journal
Cellular & Molecular Immunology
Quellenangaben
Volume: 16,
Issue: 10,
Pages: 791-799
Publisher
Nature Publishing Group
Publishing Place
Macmillan Building, 4 Crinan St, London N1 9xw, England
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
CF Monoclonal Antibodies (CF-MAB)